COVID-19 and Cardiovascular Disease
- PMID: 32200663
- DOI: 10.1161/CIRCULATIONAHA.120.046941
COVID-19 and Cardiovascular Disease
Abstract
Coronavirus disease 2019 (COVID-19) is a global pandemic affecting 185 countries and >3 000 000 patients worldwide as of April 28, 2020. COVID-19 is caused by severe acute respiratory syndrome coronavirus 2, which invades cells through the angiotensin-converting enzyme 2 receptor. Among patients with COVID-19, there is a high prevalence of cardiovascular disease, and >7% of patients experience myocardial injury from the infection (22% of critically ill patients). Although angiotensin-converting enzyme 2 serves as the portal for infection, the role of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers requires further investigation. COVID-19 poses a challenge for heart transplantation, affecting donor selection, immunosuppression, and posttransplant management. There are a number of promising therapies under active investigation to treat and prevent COVID-19.
Keywords: COVID-19; cardiovascular diseases; pandemics; severe acute respiratory syndrome coronavirus 2.
Similar articles
-
COVID-19 and the cardiovascular system.Nat Rev Cardiol. 2020 May;17(5):259-260. doi: 10.1038/s41569-020-0360-5. Nat Rev Cardiol. 2020. PMID: 32139904 Free PMC article.
-
Letter to the Editor: Angiotensin-converting enzyme 2: an ally or a Trojan horse? Implications to SARS-CoV-2-related cardiovascular complications.Am J Physiol Heart Circ Physiol. 2020 May 1;318(5):H1080-H1083. doi: 10.1152/ajpheart.00215.2020. Epub 2020 Mar 30. Am J Physiol Heart Circ Physiol. 2020. PMID: 32223552 Free PMC article. No abstract available.
-
Would ACEIs/ARBs be beneficial for COVID-19 patients without hypertension?Pharmacol Res. 2020 Sep;159:104959. doi: 10.1016/j.phrs.2020.104959. Epub 2020 Jun 4. Pharmacol Res. 2020. PMID: 32505834 Free PMC article. No abstract available.
-
ACE2, the kidney and the emergence of COVID-19 two decades after ACE2 discovery.Clin Sci (Lond). 2020 Nov 13;134(21):2791-2805. doi: 10.1042/CS20200484. Clin Sci (Lond). 2020. PMID: 33135725 Review.
-
COVID-19: A Concern for Cardiovascular Disease Patients.Cardiovasc Toxicol. 2020 Oct;20(5):443-447. doi: 10.1007/s12012-020-09596-0. Epub 2020 Jul 29. Cardiovasc Toxicol. 2020. PMID: 32729064 Free PMC article. Review.
Cited by
-
Perioperative care of the newborns with CHDs in the time of COVID-19.Cardiol Young. 2020 Jul;30(7):946-954. doi: 10.1017/S1047951120001845. Epub 2020 Jun 25. Cardiol Young. 2020. PMID: 32613934 Free PMC article.
-
A descriptive study of random forest algorithm for predicting COVID-19 patients outcome.PeerJ. 2020 Sep 9;8:e9945. doi: 10.7717/peerj.9945. eCollection 2020. PeerJ. 2020. PMID: 32974109 Free PMC article.
-
Trends in characteristics, interventions, and outcomes of hospitalized patients with COVID-19 in Canada: a multicentre prospective cohort study.Can J Anaesth. 2024 Dec;71(12):1745-1754. doi: 10.1007/s12630-024-02826-x. Epub 2024 Sep 4. Can J Anaesth. 2024. PMID: 39231882 Free PMC article.
-
Extracorporeal Membrane Oxygenation for COVID-19: Updated 2021 Guidelines from the Extracorporeal Life Support Organization.ASAIO J. 2021 May 1;67(5):485-495. doi: 10.1097/MAT.0000000000001422. ASAIO J. 2021. PMID: 33657573 Free PMC article.
-
Risk stratification and prediction of severity of COVID-19 infection in patients with preexisting cardiovascular disease.Front Microbiol. 2024 Jul 25;15:1422393. doi: 10.3389/fmicb.2024.1422393. eCollection 2024. Front Microbiol. 2024. PMID: 39119143 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous
